Table 3.

Mean (95% confidence interval) midazolam oral availability, hepatic extraction, hepatic availability, and intestinal availability in 16 elderly volunteers before and after clarithromycin (500 mg bid ×7 days) administration

	Control
N	Female, 8	Male, 8	P-value, male vs. female	All 16
Fpo	0.37 (0.26, 0.48)	0.31 (0.21, 0.41)	0.47	0.34 (0.27, 0.42)
EH	0.34 (0.27, 0.41)	0.21 (0.16, 0.25)	0.006	0.27 (0.22, 0.33)
FH	0.66 (0.59, 0.73)	0.79 (0.75, 0.84)	0.006	0.73 (0.67, 0.78)
FG	0.55 (0.42, 0.69)	0.39 (0.28, 0.50)	0.098	0.47 (0.38, 0.57)

Clarithromycin treatment
N	Female, 8	Male, 8	P-value, male vs. female	All 16	P-value, control vs. treatment
Fpo	0.72 (0.59, 0.84)	0.72 (0.63, 0.81)	0.97	0.72 (0.64, 0.79)	<0.00001
EH	0.10 (0.08, 0.13)	0.09 (0.05, 0.12)	0.46	0.09 (0.07, 0.12)	<0.00001
FH	0.90 (0.87, 0.92)	0.91 (0.88, 0.95)	0.46	0.91 (0.88, 0.93)	<0.00001
FG	0.80 (0.66, 0.94)	0.79 (0.69, 0.88)	0.89	0.79 (0.71, 0.87)	0.00002